Hepatitis C virus induces the cannabinoid receptor 1

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-10

  van der Poorten, David ^a   Shahidi, Mahsa ^a   Tay, Enoch ^a   Sesha, Jayshree ^a   Tran, Kayla ^b   McLeod, Duncan ^b   Milliken, Jane S ^b   Ho, Vikki ^a   Hebbard, Lionel W ^a   Douglas, Mark W ^a,b   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRUCTURAL PROTEIN;

ADULT; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; GENETICS; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS;

ADULT; CELL LINE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; RECEPTOR, CANNABINOID, CB1; UP-REGULATION; YOUNG ADULT;

EID: 77958571316     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012841     Document Type: Article

References (43)

1. World Health Organisation Initiative for vaccine research (IVR); Hepatitis C page. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html Accessed January 15, 2008.
2. van der Poorten D, George J (2008) Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis 12: 805-824, ix.
3. McCaughan GW, George J (2004) Fibrosis progression in chronic hepatitis C virus infection. Gut 53: 318-321.
4. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, et al. (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42: 63-71.
5. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, et al. (2003) Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125: 1695-1704.
6. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, et al. (2002) Genotypespecific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 17: 873-881.
7. Kumar D, Farrell GC, Fung C, George J (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36: 1266-1272.
8. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F (2006) Steatosis in Chronic Hepatitis C: Why does it really matter? Gut 55: 123-130.
9. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, et al. (2003) Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.[see comment]. Cancer 97: 3036-3043.
10. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. PNAS 99: 15669-15674.
11. Smart RG, Ogborne AC (2000) Drug use and drinking among students in 36 countries. Addict Behav 25: 455-460.
12. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949.
13. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
14. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S (2008) Endocannabinoids and the control of energy homeostasis. J Biol Chem 283: 33021-33025.
15. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, et al. (2001) Leptinregulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
16. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to dietinduced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28: 640-648.
17. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study G (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.[see comment]. New England Journal of Medicine 353: 2121-2134.
18. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.[see comment]. Journal of Clinical Investigation 115: 1298-1305.
19. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, et al. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676.
20. Julien, Grenard, Teixeira C, Van N, Li, et al. (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742-755.
21. Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S, Morales-Ruiz M, et al. (2008) Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324: 475-483.
22. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7: 227-235.
23. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129.
24. Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, et al. (2008) Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134: 432-439.
25. Scheuer PJ (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13: 372-374.
26. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
27. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, et al. (2003) Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125: 1808-1817.
28. Shaw ML, McLauchlan J, Mills PR, Patel AH, McCruden EA (2003) Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins. J Med Virol 70: 361-372.
29. Rasband W Image J. U.S. National Institutes of Health, Bethesda, Maryland, USA, 1997-2007.
30. Boivin B, Vaniotis G, Allen BG, Hebert TE (2008) G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J Recept Signal Transduct Res 28: 15-28.
31. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G (2006) Orexin-1 receptorcannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281: 38812-38824.
32. Negro F (2006) Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 12: 6756-6765.
33. Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, et al. (2002) Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 292: 198-210.
34. Barba G, Harper F, Harada T, Kohara M, Goulinet S, et al. (1997) Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. PNAS 94: 1200-1205.
35. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, et al. (2007) HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun 355: 883-888.
36. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, et al. (2002) Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB Journal 16: 185-194.
37. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, et al. (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118: 3160-3169.
38. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA (2004) Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126: 529-540.
39. Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, et al. (2005) Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 129: 246-258.
40. Parfieniuk A, Flisiak R (2008) Role of cannabinoids in chronic liver diseases. World J Gastroenterol 14: 6109-6114.
41. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, et al. (2002) Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99: 15669-15674.
42. Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, et al. (2008) Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology 48: 1396-1403.
43. European Medicines Agency (2008) The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. pp. London, 23 October, Doc. Ref. EMEA/CHMP/537777/532008.